- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06304571
A Study of HC006 in Subjects With Advanced Solid Tumors
March 5, 2024 updated by: HC Biopharma Inc.
A Phase I, Open-label, Dose-Escalation and Dose-expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of HC006 in Advanced Solid Tumor Subjects
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies.
This study is a first-in-human (FIH) study of HC006 in subjects with advanced solid tumors.
Study Overview
Detailed Description
HC006, a novel therapeutic monoclonal antibody that specifically binds to human C-C motif chemokine receptor 8 (CCR8) and is designed to selectively deplete tumor-infiltrating T regulatory cells (Tregs) with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).
In mouse tumor models, HC006 has demonstrated excellent antitumor activity and safety profile.
This first-in-human (FIH) study will be conducted in two parts.
In the Dose-Escalation part, testing will be done on up to 31 subjects to determine the maximum tolerated dose (MTD) and the recommended dose (RD).
In the Dose-expansion part, we will evaluate the safety and efficacy of the recommended dose of HC006 in the treatment of advanced solid tumor subjects without standard therapy.
Study Type
Interventional
Enrollment (Estimated)
76
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: langxi Zhang, PhD
- Phone Number: 00-86-021-50433368
- Email: langxi.zhang@btyy.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200120
- Recruiting
- Shanghai East Hospital
-
Contact:
- Ye Guo, MD
- Email: pattrickguo@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects must have histologically confirmed and documented diagnosis of locally advanced unresectable or metastatic advanced solid tumor that is refractory to standard treatment, or intolerant to standard treatment, or for which no standard treatment exists.
- At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1(dose escalation only requires at least one assessable lesion)
- Agree to provide archived or fresh tumor tissue samples of primary or metastatic lesions for expansion cohorts.
- Life expectancy ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Have adequate organ function as described in the protocol.
- Agree to adopt effective contraceptive measures.
Exclusion Criteria:
- Prior exposure to CCR8 inhibitor or hypersensitivity to any ingredient of the study drug.
- Treatment with any systemic anti-cancer treatment within 4 weeks before first dose of study drug.
- Use of any live attenuated vaccines within 28 days.
- With primary central nervous system (CNS) tumors or unstable CNS metastases.
- Have active or history of autoimmune disease or immunodeficiency disease.
- With active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
- With any mental or cognitive impairment that may limit their understanding, implementation.
- Major surgery within 4 weeks of study drug administration.
- Have uncontrolled or severe illness, including but not limited to severe cardiovascular disease, interstitial lung disease or non-infectious pneumonia, or uncontrollable clinical third luminal effusion.
- Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
- History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma.
- Women who are pregnant or breastfeeding.
- Other protocol defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HC006 Dose Escalation
|
Specified dose on specified days
|
Experimental: HC006 Dose Expansion
|
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Dose Limiting Toxicities(DLTs)
Time Frame: up to 24 months
|
Incidence of Dose Limiting Toxicities(DLTs)
|
up to 24 months
|
Incidence of adverse events(AEs)
Time Frame: up to 24 months
|
Incidence of adverse events(AEs)
|
up to 24 months
|
Incidence of Serious adverse events(SAEs)
Time Frame: up to 24 months
|
Incidence of Serious adverse events(SAEs)
|
up to 24 months
|
Clinically Significant changes in safety assessments
Time Frame: up to 24 months
|
Clinically Significant changes in safety assessments
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) Parameter:Maximum serum concentration (Cmax)
Time Frame: up to 24 months
|
Maximum serum concentration (Cmax)
|
up to 24 months
|
PK Parameter:Time to reach Cmax (Tmax)
Time Frame: up to 24 months
|
Time to reach Cmax (Tmax)
|
up to 24 months
|
PK Parameter:Area Under the Concentration-time Curve (AUC)
Time Frame: up to 24 months
|
Area Under the Concentration-time Curve (AUC)
|
up to 24 months
|
Immunogenicity
Time Frame: up to 24 months
|
Incidence of anti-drug antibodies (ADAs) to HC006
|
up to 24 months
|
Objective Response Rate (ORR) per RECIST 1.1
Time Frame: up to 24 months
|
The sum of the proportions of subjects who achieved CR or PR in imaging evaluation as assessed by the investigator based on RECIST1.1 criteria.
|
up to 24 months
|
progression-Free Survival (PFS) per RECIST 1.1
Time Frame: up to 24 months
|
Time from first dose of the investigational drug to PD or death from any cause.
|
up to 24 months
|
Overall Survival (OS)
Time Frame: up to 24 months
|
Time from first dose of the investigational drug to death from any cause.
|
up to 24 months
|
Disease Control Rate (DCR) per RECIST 1.1
Time Frame: up to 24 months
|
The sum of proportions of subjects who achieved CR, PR, and SD in imaging evaluation.
|
up to 24 months
|
Duration of response (DOR) per RECIST 1.1
Time Frame: up to 24 months
|
Time from the first evaluated CR or PR until PD or death from any cause.
|
up to 24 months
|
Time to progression (TTP) per RECIST 1.1
Time Frame: up to 24 months
|
Time from first dose of the investigational drug to the tumor evaluation of PD.
|
up to 24 months
|
Time To Response (TTR) per RECIST 1.1
Time Frame: up to 24 months
|
Time from first dose of the investigational drug to the first tumor evaluation of CR or PR.
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2024
Primary Completion (Estimated)
March 15, 2026
Study Completion (Estimated)
July 16, 2026
Study Registration Dates
First Submitted
March 5, 2024
First Submitted That Met QC Criteria
March 5, 2024
First Posted (Actual)
March 12, 2024
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HC006-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor